Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Focusing on lower body strength is essential as it supports daily physical activities. The article highlights six simple, ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

A physical therapist said that sitting all day can cause knee pain, but simple exercises can help strengthen and stabilize ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial ... treatment 1 from a mean baseline body weight of 113 kg, people treated ...

The randomized, double-blinded, parallel-group, superiority phase 3 STEP UP trial (ClinicalTrials.gov Identifier: NCT05646706) enrolled 1407 adults aged 18 years and older with a body mass index ...

STEP UP is a 72-week efficacy and safety trial investigating ... if all people adhered to treatment 1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved ...

The company states: “Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial ... to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide ...

Hold the bridge and sweep your left leg back until your left knee is on the floor under your hips. Lift your left hand and rise into a half-kneeling lunge. From there, swing your left leg forward and ...